GILD · Healthcare
GILEAD SCIENCES, INC.
Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: what to focus on this earnings window
News · 2026-09-22
- Revenue Performance and MixImportance 49 · Surprise 22Gilead Sciences recently reported quarterly revenue of $7.80 billion. Revenue increased 10.6% year over year, exceeding the 3% materiality threshold. The reported quarterly revenue growth accompanied an earnings beat,…
- HIV Prevention Access ExpansionImportance 31 · Surprise 42Gilead is extending royalty-free licenses for the HIV prevention medicine lenacapavir. The company also signed a new access agreement with the Pan American Health Organization. The reported actions expand access to…
- HIV Prevention Access PressureImportance 31 · Surprise 42Gilead is expanding HIV prevention access through royalty-free licenses for lenacapavir. It also signed a new access agreement with the Pan American Health Organization, broadening potential availability across the…
- Quarterly Dividend DeclarationImportance 13 · Surprise 6Gilead declared a quarterly dividend of $0.82 per share. The dividend is scheduled for payment on September 29, 2026. Shareholders of record on September 15, 2026 are eligible for the distribution.
News · 2026-09-21
- Product / Drug Pipeline ProgressImportance 31 · Surprise 42Gilead-backed Lakefront Biotherapeutics plans to initiate registrational trials for gamgertamig in 2027 for immune thrombocytopenia (ITP) and autoimmune hemolytic anemia (AIHA). Lakefront also plans to begin additional…
- Licensing / Collaboration DealsImportance 31 · Surprise 42Gilead has an alliance with Lakefront Biotherapeutics supporting development of gamgertamig, a T-cell engager for immune-mediated diseases. Lakefront plans to begin additional autoimmune basket studies in early 2027…
News · 2026-09-19
- Revenue Performance and MixImportance 47 · Surprise 22Gilead Sciences reported latest-quarter revenue of $7.80 billion. Revenue increased 10.6% year over year, exceeding the materiality threshold for mandatory inclusion. Latest quarterly earnings surpassed analysts’…
News · 2026-09-18
- Revenue Performance and MixImportance 54 · Surprise 40Gilead Sciences’ revenue increased 10.6% year over year, according to the reported second-quarter update. The digest does not provide a dollar revenue amount or segment-level breakdown. The reported growth exceeds the…
- HIV PrEP Regulatory ExpansionImportance 31 · Surprise 42Gilead entered an agreement with the Pan American Health Organization (PAHO) to expand access to lenacapavir in 14 Latin American and Caribbean countries. The twice-yearly HIV-prevention dosing is intended to improve…
News · 2026-09-17
- HIV PrEP Regulatory ExpansionImportance 34 · Surprise 42Gilead expanded six royalty-free voluntary licensing agreements for investigational once-yearly lenacapavir to generic manufacturers covering 120 high-incidence, resource-limited countries. The agreements are intended…
- HIV Prevention Access PressureImportance 34 · Surprise 42Gilead expanded royalty-free voluntary licensing for investigational once-yearly lenacapavir to generic manufacturers covering 120 high-incidence, resource-limited countries, supporting manufacturing readiness and…
News · 2026-09-16
- HIV PrEP Regulatory ExpansionImportance 31 · Surprise 42Gilead expanded six royalty-free voluntary licensing agreements for investigational once-yearly lenacapavir for HIV pre-exposure prophylaxis to 120 high-incidence countries, primarily low- and lower-middle-income…
News · 2026-09-15
- HIV PrEP Regulatory ExpansionImportance 41 · Surprise 58Gilead and the Pan American Health Organization agreed to expand access to twice-yearly lenacapavir, marketed as Yeztugo, for HIV pre-exposure prophylaxis across Latin America and the Caribbean. The arrangement uses…
- HIV Prevention Access PressureImportance 41 · Surprise 58Gilead agreed with the Pan American Health Organization (PAHO) to expand access to twice-yearly lenacapavir, marketed as Yeztugo, for HIV pre-exposure prophylaxis across PAHO Member States in Latin America and the…
- Licensing / Collaboration DealsImportance 31 · Surprise 42Gilead and the Pan American Health Organization agreed to expand access to twice-yearly lenacapavir, marketed as Yeztugo, for HIV prevention across all PAHO Member States in Latin America and the Caribbean. Fourteen…
- Quarterly Dividend DeclarationImportance 30 · Surprise 6Gilead’s dividend distribution was reported at approximately $1.02 billion, exceeding the materiality threshold for the company. The dividend was set at $0.82 per share. September 15 was the ex-dividend date, and the…
- Institutional Ownership ChangesImportance 5 · Surprise 14Bank of America reduced its Gilead stake by 6.7% during the second quarter by selling 1,329,871 shares. Following the sale, Bank of America owned 18,649,065 Gilead shares valued at more than $2.3 billion. BlackRock and…
News · 2026-09-12
- Revenue Performance and DividendImportance 37 · Surprise 6Gilead Sciences reported quarterly revenue of $7.8 billion, exceeding analyst expectations. Adjusted EPS was negative $6.75 for the quarter and also exceeded analyst expectations. The company declared a quarterly…
News · 2026-09-11
- Research Investment and CapacityImportance 58 · Surprise 42Gilead launched a 182,000-square-foot Research Center at its Foster City, California headquarters on September 11, 2026. The facility will expand oncology, inflammation, and research data-science capabilities and…
- Competition and Market Share PressureImportance 47 · Surprise 60A federal appeals court upheld a preliminary injunction blocking imports and U.S. sales of foreign-market Gilead-branded HIV medications. The Fourth Circuit found that the foreign versions were materially different…
- Litigation and Legal RiskImportance 47 · Surprise 60The Fourth Circuit Court of Appeals upheld a preliminary injunction blocking the importation and sale of foreign-market Gilead-branded HIV medications in the United States. The court found that the foreign versions…
News · 2026-09-10
- HIV PrEP Regulatory ExpansionImportance 47 · Surprise 60The UK's National Institute for Health and Care Excellence (NICE) issued draft guidance recommending against routine NHS coverage in England for Gilead's twice-yearly injectable lenacapavir (Yeztugo) for HIV…
- Product / Drug Pipeline ProgressImportance 31 · Surprise 42Gilead’s pipeline is entering an execution and prioritization phase across HIV, oncology and inflammation. Chief Medical Officer Dietmar Berger described portfolio expansion through internal development and…
- Guidance and OutlookImportance 31 · Surprise 42At healthcare-investor conferences, Gilead management described HIV, oncology, inflammation, and cell therapy as the principal areas for future growth. Chief Medical Officer Dietmar Berger said the portfolio, expanded…
- Revenue Performance and DividendImportance 29 · Surprise 22Gilead reported quarterly revenue growth of 10.6% year over year, exceeding analyst expectations. The revenue increase qualifies as material under the stated threshold for year-over-year changes above 10%. Gilead…
- HIV and PrEP Demand GrowthImportance 26 · Surprise 24Gilead expects continued growth across HIV prevention and treatment, with the Sunlenca launch identified as a long-term HIV growth driver. Management commentary also highlighted ongoing opportunities in HIV prevention…
News · 2026-09-09
- Research Investment and CapacityImportance 34 · Surprise 42Gilead Sciences opened a new 182,000-square-foot building at its Foster City, California, campus. The facility will house oncology and scientific research activities and accommodate approximately 325 employees. Gilead…
- Strategic InitiativesImportance 34 · Surprise 42Gilead Sciences opened a 182,000-square-foot facility at its existing Foster City, California, campus on September 9, 2026. The building will house oncology and scientific research activities and accommodate…
- Competition and Market Share PressureImportance 8 · Surprise 24Bristol Myers Squibb reported positive mid-stage results for its investigational multiple myeloma CAR T therapy, arlocabtagene autoleucel, in relapsed and refractory disease. The results showed significant improvements…
News · 2026-09-08
- Research Investment and CapacityImportance 64 · Surprise 42Gilead inaugurated a 182,000-square-foot Research Center at its Foster City headquarters. The facility is part of a planned $32 billion U.S. investment in research, development, and manufacturing through 2030. The…
- Revenue Performance and MixImportance 30 · Surprise 22Gilead reported second-quarter revenue of approximately $7.80 billion, up 10.6% year over year and above analyst expectations. The company nevertheless reported a net loss of $6.75 per share for the quarter. Reports…
- Quarterly Dividend DeclarationImportance 13 · Surprise 6Gilead declared a quarterly dividend of $0.82 per share. The dividend was reported alongside second-quarter revenue of approximately $7.80 billion and strong free cash flow. Biktarvy’s cash generation was identified as…
News · 2026-09-07
- Regulatory Approval MilestonesImportance 47 · Surprise 60The FDA approved Bixlenvo, a once-daily single-tablet regimen for virologically suppressed adults with HIV. Bixlenvo combines bictegravir 75 mg with lenacapavir 50 mg and is positioned as the first and only…
News · 2026-09-05
- Revenue Performance and MixImportance 30 · Surprise 22Gilead reported second-quarter revenue of approximately $7.80 billion, up 10.6% year over year and above analyst expectations. The company nevertheless reported a net loss of $6.75 per share for the quarter. Reports…
News · 2026-09-04
- Strategic InitiativesImportance 64 · Surprise 42Gilead inaugurated a 182,000-square-foot Research Center at its Foster City headquarters on September 8, 2026. The facility will support oncology, inflammation, and research data science and is designed to accommodate…
News · 2026-09-03
- Strategic InitiativesImportance 64 · Surprise 42Gilead inaugurated a 182,000-square-foot Research Center at its Foster City headquarters on September 8, 2026. The facility will support oncology, inflammation, and research data science and is designed to accommodate…
News · 2026-09-02
- Strategic InitiativesImportance 64 · Surprise 42Gilead inaugurated a 182,000-square-foot Research Center at its Foster City headquarters on September 8, 2026. The facility will support oncology, inflammation, and research data science and is designed to accommodate…
News · 2026-09-01
- Revenue Performance and DividendImportance 47 · Surprise 22Gilead Sciences reported quarterly revenue of $7.80 billion, exceeding analyst expectations. Revenue increased 10.6% year over year. The company declared a quarterly dividend of $0.82 per share.
News · 2026-08-28
- Product / Drug Pipeline ProgressImportance 38 · Surprise 60Gilead Sciences received U.S. Food and Drug Administration approval for Bixlenvo on August 28, 2026. Bixlenvo is a once-daily HIV regimen intended for adults living with HIV infection. The regimen offers a smaller…
- Regulatory Approval MilestonesImportance 38 · Surprise 60Gilead Sciences received FDA approval for Bixlenvo, a once-daily HIV treatment regimen for adults living with HIV infection. The product is positioned as a smaller single-tablet option for patients currently using…
News · 2026-08-27
- Regulatory Approval MilestonesImportance 65 · Surprise 60The U.S. FDA approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), a once-daily single-tablet regimen for virologically suppressed adults with HIV. Bixlenvo is the first and only single-tablet regimen for…
- Product Launch and TransitionImportance 58 · Surprise 42The U.S. FDA approved Gilead’s Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), a once-daily single-tablet regimen for virologically suppressed adults with HIV. Bixlenvo is positioned as the first and only…
News · 2026-08-26
- Institutional Ownership ChangesImportance 20 · Surprise 24Ancora Advisors acquired 121,465 Gilead shares valued at approximately $15.35 million, while CastleArk Management acquired 527,542 shares valued at approximately $66.65 million. Canada Pension Plan Investment Board…
- Revenue Performance and DividendImportance 20 · Surprise 6Gilead recently reported quarterly revenue of approximately $7.8 billion, described as exceeding analyst estimates. The reported revenue figure was above the materiality threshold of $234 million for this company.…
News · 2026-08-25
- Regulatory Approval MilestonesImportance 16 · Surprise 60The European Commission approved a label expansion for Gilead Sciences’ Trodelvy in combination with Keytruda. The authorization permits first-line use in metastatic triple-negative breast cancer (TNBC) in the European…
- Oncology Product ExpansionImportance 16 · Surprise 60The European Commission approved a label expansion for Gilead’s Trodelvy in combination with Merck’s Keytruda. The approval covers first-line treatment of metastatic triple-negative breast cancer (TNBC) in the European…
- Quarterly Dividend DeclarationImportance 10 · Surprise 6Gilead reported quarterly revenue of approximately $7.8 billion, exceeding analyst estimates. The company declared a quarterly dividend of $0.82 per share. The dividend declaration represents a recurring…
- Institutional Ownership ChangesImportance 3 · Surprise 6Legal & General Group Plc acquired more than 10.4 million Gilead shares during the second quarter for approximately $1.3 billion. The Manufacturers Life Insurance Company purchased more than 1 million shares valued at…
News · 2026-08-24
- Oncology Product ExpansionImportance 47 · Surprise 60The European Commission approved Trodelvy in combination with Merck’s Keytruda for first-line treatment of adults with PD-L1-positive, unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC)…
- Revenue Performance and MixImportance 37 · Surprise 6Gilead Sciences reported second-quarter revenue of approximately $7.80 billion. The quarterly revenue exceeded analyst estimates, representing a material revenue figure relative to the company’s stated revenue base.…
- Quarterly Dividend DeclarationImportance 6 · Surprise 6Gilead Sciences declared a quarterly dividend of $0.82 per share. The dividend is scheduled to be paid on September 29, 2026. The digest does not state a year-over-year dividend change, record date, or total cash…
News · 2026-08-23
- Revenue Performance and MixImportance 37 · Surprise 6Gilead Sciences reported second-quarter revenue of approximately $7.80 billion. The quarterly revenue exceeded analyst estimates, representing a material revenue figure relative to the company’s stated revenue base.…
- Quarterly Dividend DeclarationImportance 6 · Surprise 6Gilead Sciences declared a quarterly dividend of $0.82 per share. The dividend is scheduled to be paid on September 29, 2026. The digest does not state a year-over-year dividend change, record date, or total cash…
News · 2026-08-22
- Revenue Performance and MixImportance 37 · Surprise 6Gilead Sciences reported recent quarterly revenue of approximately $7.80 billion. The quarterly revenue exceeded analyst estimates. Third-party reports characterized the company’s quarterly revenue growth as strong,…
- Quarterly Dividend DeclarationImportance 9 · Surprise 6Gilead Sciences declared a quarterly dividend of $0.82 per share. The dividend announcement was cited in multiple reports alongside the company’s recent quarterly results. At the reported share price of approximately…
News · 2026-08-21
- Revenue Performance and MixImportance 37 · Surprise 6Gilead Sciences reported recent quarterly revenue of approximately $7.80 billion. The quarterly revenue exceeded analyst estimates. Third-party reports characterized the company’s quarterly revenue growth as strong,…
- Quarterly Dividend DeclarationImportance 9 · Surprise 6Gilead Sciences declared a quarterly dividend of $0.82 per share. The dividend announcement was cited in multiple reports alongside the company’s recent quarterly results. At the reported share price of approximately…
News · 2026-08-20
- Revenue Performance and MixImportance 47 · Surprise 22Gilead Sciences reported quarterly revenue of approximately $7.8 billion for the second quarter of 2026. Revenue increased 10.6% year over year, exceeding the materiality threshold and indicating strong annual growth.…
News · 2026-08-19
- Revenue Performance and MixImportance 47 · Surprise 22Gilead Sciences reported quarterly revenue of approximately $7.8 billion for the second quarter of 2026. Revenue increased 10.6% year over year, exceeding the materiality threshold and indicating strong annual growth.…
- Quarterly Dividend DeclarationImportance 13 · Surprise 6Gilead Sciences declared a quarterly dividend of $0.82 per share following its second-quarter 2026 results. The dividend was reported alongside quarterly revenue of approximately $7.8 billion, which exceeded analyst…